, Volume 9, Issue 3, pp 279–289

Id-1 expression and cell survival


DOI: 10.1023/B:APPT.0000025804.25396.79

Cite this article as:
Wong, YC., Wang, X. & Ling, MT. Apoptosis (2004) 9: 279. doi:10.1023/B:APPT.0000025804.25396.79


The Id (inhibitor of differentiation or DNA binding) helix-loop-helix (HLH) proteins are a group of dominant negative regulators of basic HLH transcriptional factors which promote cell differentiation. Recent evidence has revealed that Id proteins, especially Id-1, are also able to promote cell proliferation and cell cycle progression through inactivation of tumour suppressor and activation of growth promoting pathways in mammalian cells. In addition, upregulation of Id-1 has been found in many types of human cancer and its expression levels are also associated with advanced tumour stage. Furthermore, ectopic expression of Id-1 in human cancer cells is able to induce cell proliferation under sub-optimal conditions and protect the cells against apoptosis. These lines of evidence strongly indicate Id-1 as a positive regulator of cell growth and its expression may be a key factor required for tumour cell proliferation. This review will discuss recent evidence on the role of Id-1 in cell proliferation and survival, and its significance in malignant transformation. In addition, we will highlight the recent development in the understanding of the molecular mechanisms responsible for the action of Id-1 in promoting cell survival and tumourigenesis. Finally, the therapeutic implications through inactivation of Id-1 in the treatment of human cancer will also be addressed.

cell proliferation Id-1 survival tumour progression 

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  1. 1.Department of Anatomy, Cancer Biology Lab, Faculty of Medicine, Central Laboratory of Institute of Molecular Technology for Drug Discovery and SynthesisThe University of Hong KongHong Kong, SARChina
  2. 2.Department of Anatomy, Cancer Biology LabThe University of Hong KongHong Kong, SARChina

Personalised recommendations